Neuralstem in the News
“Stem cell therapy helps paraplegic rats regain movement”
NSI-566/spinal cord injury animal research, following report in the scientific journal CELL, is reported by UK-based industry publication.
“Paralyzed Rats Walk Again After Stem Cell Transplant:
The rodent recovery spurs hope that humans could one day benefit from similar treatments.”
Susan Young, who recently reported on progress of NSI-566 cell therapy in the ongoing ALS trial, examines CELL spinal cord injury research study, noting promise of both clinical and pre-clinical trials utilizing NSI-566 neural stem cells.
"Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats"
“…the last piece of the puzzle…” to move Neuralstem’s human spinal cord injury trial forward is projected by Neuralstem’s CEO Richard Garr in this article focused on the SCI study published in scientific journal CELL.
"Stem Cells Help Rats Recover Lower-Body Movement"
Neuralstem’s NSI-566 cells in spinal cord injury animal study, where six transplanted paraplegic rats recovered movement in all lower joints, is reported in GEN, following publication in the scientific journal CELL.
Neuralstem Overview Article by John H. Ford
Comprehensive, to-the-minute overview article of Neuralstem’s progress in both its stem cell therapy and neurogenic pharmaceutical divisions. Includes promise of hope: “With all these indications, any level of success with these other incurable conditions could provide tremendous hope and relief for millions of patients.”
- Game Changer for the Human Genome Sector?
- Henry County man undergoes experimental ALS stem cell surgery
- Miracle Improvement In ALS Patient Could Force Pharma To Get Serious On Stem Cell Therapy
- New Cells for ALS Patients: Surgeons have transplanted a second dose of neural cells into a patient’s spinal cord in a pioneering trial.
- Landmark Surgery for ALS Patient Ted Harada Set for Today
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.